Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCD
MCID: MLT113
MIFTS: 47

Multicentric Castleman Disease (MCD)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Multicentric Castleman Disease

About this section

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 12 20 15
Plasmablastic Multicentric Castleman Disease 12 20
Multicentric Giant Lymph Node Hyperplasia 12 20
Multi-Centric Castleman's Disease 44 70
Pmcd 12 20
Mcd 12 20
Human Herpesvirus-8-Negative Multicentric Castleman Disease 58
Multicentric Plasma Cell Variant of Castleman's Disease 20
Hhv-8-Negative Multicentric Castleman Disease 58
Idiopathic Multicentric Castleman's Disease 20
Idiopathic Multicentric Castleman Disease 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0111152
MeSH 44 C537372
NCIt 50 C27855
ICD10 via Orphanet 33 D47.7
Orphanet 58 ORPHA570431
UMLS 70 C1334815
Sources

Summaries for Multicentric Castleman Disease

About this section
GARD : 20 Multicentric Castleman disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes (as opposed to unicentric Castleman disease, which involves a single lymph node or single region of lymph nodes). The signs and symptoms of MCD are often nonspecific, and are mild in some people but life-threatening in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. The disease is diagnosed based on the symptoms present, laboratory test results, imaging studies, and results of a biopsy of the lymph nodes which shows specific features when studied under the microscope. In some cases, MCD is caused by human herpesvirus-8 (HHV-8) and is referred to as HHV-8-associated MCD. In other cases, the cause is not known and it is referred to as HHV-8 negative MCD, or idiopathic MCD (iMCD). Treatment of MCD is challenging, and treatment options and outcomes depend on the type and severity in each person.

MalaCards based summary : Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to polyclonal hypergammaglobulinemia and castleman disease, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Siltuximab and Zanubrutinib have been mentioned in the context of this disorder. Affiliated tissues include lymph node, spleen and bone marrow, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Sources

Related Diseases for Multicentric Castleman Disease

About this section

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 696)
# Related Disease Score Top Affiliating Genes
1 polyclonal hypergammaglobulinemia 31.0 IL6 CXCL13 CRP CD4
2 castleman disease 30.9 VEGFA TNFRSF8 SDC1 MTOR KRT15 IL6
3 pneumonia 30.6 IL6 IL10 IFNG CRP
4 interstitial lung disease 30.6 IL6 IL10 IFNG CRP
5 latent syphilis 30.5 CXCL13 CD4
6 papilledema 30.5 VEGFA CRP CD4
7 human immunodeficiency virus type 1 30.5 IL10 IFNG CD4 CD38 CCL4
8 bacterial sepsis 30.5 IL6 IL10 CRP
9 pancytopenia 30.5 IL6 IFNG H2AC18 CRP CD4
10 lung disease 30.5 VEGFA IL6 IL10 IFNG CRP
11 angioimmunoblastic t-cell lymphoma 30.4 VEGFA TNFRSF8 CXCL13
12 mesangial proliferative glomerulonephritis 30.4 IL6 CFHR2 CD79A
13 osteosclerotic myeloma 30.4 VEGFA IL6
14 cellulitis 30.4 IL6 CRP CD4
15 mikulicz disease 30.4 IL10 CRP CD4
16 herpes zoster 30.4 IL10 IFNG CD4
17 brucellosis 30.4 IL6 IL10 IFNG CRP
18 deficiency anemia 30.4 IRF4 IL6 H2AC18 CRP CFHR2 CD4
19 familial mediterranean fever 30.4 IL6 IL10 CRP
20 thrombocytopenia 30.3 TNFRSF8 PAX5 IRF4 IL6 IL10 IFNG
21 lymphoma 30.3 TNFRSF8 PAX5 IRF4 IL6 CXCL13 CD38
22 glomeruloid hemangioma 30.3 VEGFA TNFRSF8 SDC1 IL6
23 urticaria 30.3 IL6 IL10 CRP CD4
24 autoimmune lymphoproliferative syndrome 30.2 MTOR IL10 H2AC18 CD4
25 autoimmune disease 30.2 IL6 IL10 IFNG CRP CD79A
26 purpura 30.2 IL6 IL10 IFNG CRP CD79A
27 oral tuberculosis 30.1 IFNG CRP CD4
28 exanthem 30.1 VEGFA MTOR IL6 IL10 IFNG H2AC18
29 severe acute respiratory syndrome 30.1 IL6 IL10 IFNG CRP
30 syphilis 30.1 IL6 IFNG CRP CD79A CD4
31 mycobacterium tuberculosis 1 30.1 IL10 IFNG H2AC18 CD4 CCL4
32 rheumatoid arthritis 30.0 VEGFA IL6 IL10 IFNG CRP CD79A
33 tetanus 29.9 IL6 IL10 IFNG CRP CD79A
34 respiratory failure 29.8 VEGFA SDC1 IL6 IL10 H2AC18 CRP
35 pericardial effusion 29.8 VEGFA TNFRSF8 IL6 CRP CD4
36 acquired immunodeficiency syndrome 29.7 IL6 IL10 IFNG CRP CD79A CD4
37 lymphoma, non-hodgkin, familial 29.6 TNFRSF8 SDC1 PAX5 IRF4 IL6 H2AC18
38 common variable immunodeficiency 29.6 TNFRSF8 IRF4 IL6 IL10 IFNG CD79A
39 plasmacytoma 29.6 VEGFA PAX5 IRF4 IL6 CD79A CD38
40 peripheral nervous system disease 29.5 VEGFA MTOR IL6 IL10 IFNG H2AC18
41 immune deficiency disease 29.4 TNFRSF8 IL6 IL10 IFNG H2AC18 CRP
42 disease by infectious agent 29.3 TNFRSF8 IL6 IL10 IFNG H2AC18 CRP
43 diffuse large b-cell lymphoma 28.9 VEGFA TNFRSF8 SDC1 PAX5 IRF4 IL6
44 myeloma, multiple 28.9 VEGFA SDC1 MTOR IRF4 IL6 IL10
45 systemic lupus erythematosus 28.1 VEGFA SDC1 MTOR IRF4 IL6 IL10
46 macular dystrophy, corneal 11.6
47 malonyl-coa decarboxylase deficiency 11.5
48 hhv-8-associated multicentric castleman disease 11.5
49 multiple carboxylase deficiency 11.4
50 holocarboxylase synthetase deficiency 11.4

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease
Sources

Symptoms & Phenotypes for Multicentric Castleman Disease

About this section

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 CD38 CD4 CD79A CXCL13 IFNG IL10
2 hematopoietic system MP:0005397 9.97 CD38 CD4 CD79A CXCL13 IFNG IL10
3 immune system MP:0005387 9.8 CD38 CD4 CD79A CRP CXCL13 IFNG
4 neoplasm MP:0002006 9.23 CD79A IFNG IL10 IL6 IRF4 PAX5
Sources

Drugs & Therapeutics for Multicentric Castleman Disease

About this section

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Siltuximab Approved, Investigational Phase 2 541502-14-1
2
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
5
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
6
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
9
Zidovudine Approved Phase 2 30516-87-1 35370
10
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
11
Lenograstim Approved, Investigational Phase 2 135968-09-1
12
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
13 Analgesics Phase 2
14 Histamine H1 Antagonists Phase 2
15 Antipyretics Phase 2
16 Histamine Antagonists Phase 2
17 Pharmaceutical Solutions Phase 2
18 Protein Kinase Inhibitors Phase 2
19 Antifungal Agents Phase 2
20 Antimetabolites Phase 2
21 Anti-Retroviral Agents Phase 2
22 Anti-HIV Agents Phase 2
23 Reverse Transcriptase Inhibitors Phase 2
24 interferons Phase 2
25 Interferon-alpha Phase 2
26 Ganciclovir triphosphate Phase 2
27 Antibodies Phase 2
28 Immunoglobulins Phase 2
29 Antibodies, Monoclonal Phase 2
30
Methotrexate Approved Phase 1 1959-05-2, 59-05-2 126941
31
Levoleucovorin Approved, Investigational Phase 1 68538-85-2 149436
32
Daunorubicin Approved Phase 1 20830-81-3 30323
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
34 Vitamin B9 Phase 1
35 Folic Acid Antagonists Phase 1
36 Immunoglobulins, Intravenous Phase 1
37 Keratolytic Agents Phase 1
38 Dermatologic Agents Phase 1
39 Vitamin B Complex Phase 1
40 Folate Phase 1
41 Podophyllotoxin Phase 1 518-28-5

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease Completed NCT01400503 Phase 2 Siltuximab
4 Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease Completed NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
5 The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial Recruiting NCT04743687 Phase 2 Zanubrutinib
6 Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03982771 Phase 2 Bortezomib;Cyclophosphamide;Dexamethason
7 A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Recruiting NCT03933904 Phase 2 Sirolimus
8 Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
9 Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Active, not recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
10 LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial Not yet recruiting NCT04585893 Phase 2 Rituximab;Etoposide
11 Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) Terminated NCT00127569 Phase 2 Rituximab
12 Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
13 Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
14 A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda Recruiting NCT03864419 Phase 1 Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Sources

Genetic Tests for Multicentric Castleman Disease

About this section
Sources

Anatomical Context for Multicentric Castleman Disease

About this section

MalaCards organs/tissues related to Multicentric Castleman Disease:

40
Lymph Node, Spleen, Bone Marrow, Cortex, B Cells, Endothelial, Kidney
Sources

Publications for Multicentric Castleman Disease

About this section

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 533)
# Title Authors PMID Year
1
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. 20 61
30181172 2018
2
Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. 61
33389670 2021
3
Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease. 61
33787862 2021
4
Response assessment and salvage indication for idiopathic multicentric Castleman disease. 61
33215565 2021
5
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. 61
32088937 2021
6
Extracorporeal cardiopulmonary resuscitation in a woman with twin pregnancy. 61
33739195 2021
7
A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. 61
33804823 2021
8
Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. 61
33676575 2021
9
18F-FDG PET/CT imaging features of patients with multicentric Castleman disease. 61
33741858 2021
10
Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. 61
33043529 2021
11
Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression. 61
33555231 2021
12
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. 61
33720337 2021
13
Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report. 61
33669083 2021
14
Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. 61
32715375 2021
15
Pathologically confirmed oesophageal involvement in idiopathic multicentric Castleman disease mimicking early oesophageal cancer. 61
32885232 2021
16
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. 61
33249497 2021
17
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply. 61
33253362 2021
18
HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. 61
32772106 2021
19
UCD with MCD-like inflammatory state: surgical excision is highly effective. 61
33570636 2021
20
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. 61
33128769 2021
21
Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. 61
33215784 2021
22
Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab. 61
33269653 2021
23
An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease. 61
33777463 2021
24
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. 61
33558024 2021
25
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. 61
32425294 2021
26
Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene. 61
32830263 2021
27
Updates on the diagnosis and management of multicentric Castleman disease. 61
33505874 2021
28
Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. 61
33273183 2021
29
Human herpesvirus-8-positive primary effusion lymphoma in HIV-negative patients: Single institution case series with a multidisciplinary characterization. 61
32975904 2021
30
CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus. 61
33092788 2020
31
Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells. 61
33328303 2020
32
A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review. 61
33268763 2020
33
Long-term outcome of custom toric intraocular lens for treating high astigmatism in case of cataract associated with pellucid marginal corneal degeneration. 61
33245061 2020
34
Multicentric Plasma-Cell Type Castleman Disease Masquerading As Hodgkin Lymphoma: A Case Report. 61
33268942 2020
35
Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature. 61
33276741 2020
36
An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant). 61
33327255 2020
37
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. 61
32894785 2020
38
Borderline Case of TAFRO Syndrome and POEMS Syndrome. 61
33328401 2020
39
Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease. 61
32759587 2020
40
Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease. 61
33321725 2020
41
Multicentric Castleman disease presenting as a chylous pleural effusion. 61
32950896 2020
42
Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease. 61
33229481 2020
43
Cerebral thrombotic event as a rare complication in a young female patient with idiopathic multicentric castleman disease. 61
33032104 2020
44
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. 61
32852137 2020
45
Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab. 61
33148595 2020
46
"Chronic Disseminated Aspergillosis," a Novel Fungal Immune Reconstitution Inflammatory Syndrome. 61
33204743 2020
47
Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. 61
33225930 2020
48
Germinotropic lymphoproliferative disorder: a systematic review. 61
32307569 2020
49
Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report. 61
33195662 2020
50
Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. 61
31829070 2020
Sources

Variations for Multicentric Castleman Disease

About this section
Sources

Expression for Multicentric Castleman Disease

About this section
Search GEO for disease gene expression data for Multicentric Castleman Disease.
Sources

Pathways for Multicentric Castleman Disease

About this section

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.94 VEGFA TNFRSF8 MTOR IRF4 IL6 IL10
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.26 VEGFA TNFRSF8 IRF4 IL6 IL10 IFNG
3
Allograft rejection 1 36
Show member pathways
 12.76 VEGFA IL6 IL10 IFNG CXCL13 CD4
4
T cell receptor signaling pathway 36
Show member pathways
 12.42 MTOR IRF4 IL6 IL10 IFNG CD4
5
Th17 cell differentiation 36
Show member pathways
 12.38 MTOR IRF4 IL6 IL10 IFNG CD4
6
JAK-STAT signaling pathway 36
Show member pathways
 12.32 MTOR IL6 IL10 IFNG
7
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.24 IL6 IL10 CXCL13 CCL4
8
NF-kappaB Signaling 4
12.21 TNFRSF8 PAX5 IRF4 IL10 IFNG CD79A
9
Interleukin-4 and 13 signaling 65
11.88 VEGFA IRF4 IL6 IL10
10
IL12-mediated signaling events 1
Show member pathways
 11.86 MTOR IFNG CD4 CCL4
11
HIF-1 signaling pathway 36
11.83 VEGFA MTOR IL6 IFNG
12
Innate Lymphoid Cell Differentiation Pathways 64
11.68 IRF4 IL10 IFNG CD4
13
Th1 Differentiation Pathway 64
Show member pathways
 11.64 IL6 IL10 IFNG CD4
14
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 VEGFA IL6 IFNG
15
IL4-mediated signaling events 1
11.57 MTOR IRF4 IL10
16
IgA-Producing B Cells in the Intestine 64
11.55 PAX5 IL6 IL10 CXCL13
17
Interleukin-10 signaling 65
11.45 IL6 IL10 CCL4
18
Th2 Differentiation Pathway 64
11.41 IL10 IFNG CD4
19
Malaria 36
11.32 SDC1 IL6 IL10 IFNG
20
African trypanosomiasis 36
11.31 IL6 IL10 IFNG
21
Dendritic Cells Developmental Lineage Pathway 64
11.3 IRF4 IL6 IL10 IFNG CD4 CD38
22
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.29 IL10 IFNG CCL4
23
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.23 SDC1 IL6 IL10 IFNG CD79A CD4
24
Cytokines and Inflammatory Response 1
11.02 IL6 IL10 IFNG CD4
Sources

GO Terms for Multicentric Castleman Disease

About this section

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 VEGFA MTOR IL6 IFNG CRP
2 inflammatory response GO:0006954 9.77 SDC1 IL6 CXCL13 CRP CCL4
3 positive regulation of protein phosphorylation GO:0001934 9.76 VEGFA MTOR IFNG CD4
4 immune response GO:0006955 9.73 IL6 IL10 IFNG CXCL13 CD4 CCL4
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 VEGFA IL6 IFNG
6 positive regulation of endothelial cell proliferation GO:0001938 9.69 VEGFA MTOR IL10
7 response to glucocorticoid GO:0051384 9.65 SDC1 IL6 IL10
8 humoral immune response GO:0006959 9.58 PAX5 IL6 IFNG
9 positive regulation of MHC class II biosynthetic process GO:0045348 9.54 IL10 IFNG
10 response to activity GO:0014823 9.5 MTOR IL6 IL10
11 negative regulation of lipid storage GO:0010888 9.49 IL6 CRP
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.46 VEGFA MTOR IL6 CD4
13 T-helper 17 cell lineage commitment GO:0072540 9.43 IRF4 IL6
14 cytokine-mediated signaling pathway GO:0019221 9.17 VEGFA SDC1 IRF4 IL6 IL10 CD4
15 macrophage differentiation GO:0030225 9.13 VEGFA IFNG CD4

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.61 VEGFA SDC1 MTOR CRP CFHR2 CD79A
2 cytokine activity GO:0005125 9.1 VEGFA IL6 IL10 IFNG CXCL13 CCL4
Sources

Sources for Multicentric Castleman Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....